News Agency
Men's Weekly

First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat

  • Written by PR Newswire

STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. This milestone marks an important step toward a new treatment for the approximately 190 million...

Read more: First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat

How Pallet Racking Systems Improve Warehouse Organisation and Productivity

Warehouses and distribution centres play a vital role in modern supply chains. As businesses manage increasing inventory volumes and faster delivery expectations, efficient storage systems have become more important than ever. One of the most effective solutions used by warehouses... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion